Immunotherapeutics for schizophrenia

Post Reply
User avatar
TimGDixon
Posts: 3836
Joined: Fri Mar 18, 2022 12:00 pm

Immunotherapeutics for schizophrenia

Post by TimGDixon »

05-17-2021 Treatment of Major Depressive Disorder by Low Dose Interleukin-2

https://therapeuticsolutionsint.com/the ... ression-i/

Disclosed are methods, compositions of matter, and protocols useful for treatment of major depressive disorder through administration of low dose interleukin-2 at a concentration and/or frequency sufficient to increase expansion of T regulatory cell numbers and/or enhancement of T regulatory cell activity. In some embodiments administration of interleukin-2 is provided as means of enhancing efficacy of standard antidepressant therapies. Furthermore, administration of interleukin-2 receptor agonists is also described in the current invention as a treatment of major depressive disorder.

03-04-2021 Therapeutic Monocytes for Prevention of Suicidal Ideation

https://therapeuticsolutionsint.com/the ... revention/

The invention discloses compositions of matter, protocols, and therapeutic means for treatment of suicidal ideations and/or suppression of suicidal attempts. In one embodiment the invention provides the use of umbilical cord derived monocytes as a means of treatment. In another embodiment, monocytes are de-differentiated from adult monocytes using reprogramming means to create monocyte capable of producing anti-inflammatory as well as regenerative properties useful in reducing suicidal ideations and/or attempts.

09-24-2020 Personalized Immunotherapies for Reduction of Brain Inflammation and Suicide Prevention

https://therapeuticsolutionsint.com/the ... l-therapy/

Disclosed are means, methods and compositions of matter useful for reduction of brain inflammation and prevention of suicidal ideations and suicidal attempts. In one embodiment the invention provides utilization of autologous platelet rich plasma, alone, or admixed with regenerative/anti-inflammatory adjuvants, for reduction of neural inflammation. In one embodiment autologous PRP is admixed with oxytocin and administered intranasally in a patient at risk of suicidal ideation. In another embodiment, PRP is admixed with fortified and non-fortified nigella sativa oil and administered intranasally. Other embodiments include utilization of autologous stromal vascular fraction cells alone and/or admixed with regenerative/anti-inflammatory adjuvants.

09-14-2020 Immunotherapy of Schizophrenia and Schizophrenia Associated Suicidal Ideation/Suicide

https://therapeuticsolutionsint.com/the ... zophrenia/

Disclosed are methods, means, and protocols of modifying the immune system so as to induce an immunologically tolerant state insofar as T regulatory cell number and/or activity is augmented in a patient suffering from schizophrenia. In one embodiment T regulatory cells are administered to the patient from exogenous sources, be they allogeneic or autologous. In other embodiments, T regulatory cells are generated endogenously through administration of immature dendritic cells, mesenchymal stem cells, and/or pharmaceutical means.

08-21-2020 Methods of Determining Risk of Suicide and/or Suicidal Ideation by Immunological Assessment

https://therapeuticsolutionsint.com/the ... l-markers/

Disclosed are means and methods of identifying risk of suicide and/or suicidal ideation by assessment of immunologically related cytokines and cells. In one embodiment, a score, termed the “Campbell Score” is devised based on assessment of serum cytokines, ability of immune cells to make cytokines when stimulated ex vivo, and ability of immune cells to produce neurotransmitters when stimulated ex-vivo. In one embodiment the concentration of interleukin-6 is utilized as a means of assessing suicidal propensity along, and/or in combination with metabolites of the enzyme indolamine 2,3 deoxygenase.
“And the corner sign says it's closing time so I'll bid farewell and be down the road...”
Post Reply